ALOCRIL
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALOCRIL is an ophthalmic small-molecule solution approved in 1999 for eye-related indications. The exact mechanism of action and indication are not publicly detailed in this dataset, but it is administered as eye drops. This product represents a mature, established therapy in the ophthalmology space.
LOE Approaching
With LOE approaching and no linked job openings, this product is in managed decline; expect smaller commercial teams focused on retention over growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and the product in LOE-approaching stage, ALOCRIL offers limited active career growth opportunities. Roles available would primarily support market defense and managed decline rather than expansion or innovation.
Brand ManagerMedical Science Liaison
Worked on ALOCRIL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.